Novel oxazolidinone-quinolone hybrid antimicrobials

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 23, 2003, Pages 4213-4216

  Gordeev, Mikhail F ^a   Hackbarth, Corinne ^a   Barbachyn, Michael R ^b   Banitt, Lee S ^b   Gage, James R ^b   Luehr, Gary W ^a   Gomez, Marcela ^a   Trias, Joaquim ^a   Morin, Sara E ^b   Zurenko, Gary E ^b   Parker, Christian N ^b   Evans, Jonathan M ^b   White, Richard J ^a   Patel, Dinesh V ^a  

^a Vicuron Pharmaceuticals   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; DNA TOPOISOMERASE IV; EPEREZOLID; GYRASE INHIBITOR; LEVOFLOXACIN; LINEZOLID; OFLOXACIN; OXAZOLIDINONE DERIVATIVE; PROTEIN; QUINOLONE DERIVATIVE; TOSUFLOXACIN;

ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; NONHUMAN; PHARMACOPHORE; PROTEIN SYNTHESIS; STRUCTURE ACTIVITY RELATION;

ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; NEGIBACTERIA; POSIBACTERIA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 10744224468     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.07.021     Document Type: Article

References (22)

1. Barbachyn, M. R.; Brickner, S. J.; Cleek, G. J.; Gadwood, R. C.; Greg, K. C.; Hendges, S. K.; Hutchinson, D. K.; Manninen, P. R.; Munesada, K.; Thomas, R. C; Thomasco, L. M.; Toops, D. S.; Ulanowicz, D. A. In Anti-infectives: Recent Advances in Chemistry and Structure-activity Relationships; Bentley, P. H., O'Hanlon, P. J., Eds.; The Royal Society of Chemistry, Hartnolls: Bodmin, 1997; p 15.
2. Ford C.W., Hamel J.C., Stapert D., Moerman J.K., Hutchinson D.K., Barbachyn M.R., Zurenko G.E. Trends Microbiol. 5:1997;196.
3. Gadwood, R. C.; Shinabarger, D. A. In Annual Reports in Medicinal Chemistry. Academic: San Diego, 2000; p 135.
4. Zurenko G.E., Gibson J.K., Shinabarger D.L., Aristoff P.A., Ford C.W., Tarpley W.G. Curr. Opin. Pharmacol. 1:2001;470.
5. Gordeev M.F. Curr. Opin. Drug Disc. Develop. 4:2001;450.
6. Clemett D., Markham A. Drugs. 59:2000;815.
7. Fung H.B., Kirschenbaum H.L., Ojofeitimi B.O. Clin. Ther. 23:2001;356.
8. Gootz, T. D.; Brighty, K. E. In The Quinolones, 2nd ed.; Andriole, V. T., Ed.; Academic: San Diego, 1998; p 29.
9. For an early partial disclosure of this work, see: Gordeev, M. F.; Patel, D. V.; Barbachyn, M. R.; Gage, J. R. PCT Patent Application WO 02/059116, Aug. 1, 2002; Chem. Abstr. 2002, 137, 125148.
10. Similar approach, including the compound 2, has been recently reported: Hubschwerlen C., Specklin J.-L., Sigwalt C., Schroeder S., Locher H.H. Bioorg. Med. Chem. 11:2003;2313.
11. Alovero F., Nieto M., Mazzieri M.R., Then R., Manzo R.H. Antimicrob. Agents Chemother. 42:1998;1495.
12. Albrecht H.A., Beskid G., Christenson J.G., Georgopapadakou N.H., Keith D.D., Konzelmann F.M., Pruess D.L., Rossman P.L., Wei C.-C. J. Med. Chem. 34:1991;2857.
13. Hershberger P.M., Demuth T.P. Jr. Adv. Exp. Med. Biol. 456:1998;239.
14. Gonzales R.D., Schreckenberger P.C., Graham M.B., Kelkar S., DenBesten K., Quinn J.P. Lancet. 357:2001;1179.
15. Herrero I.A., Issa N.C., Patel R. New Engl. J. Med. 346:2002;867.
16. Tsiodras S., Gold H.S., Sakoulas G., Eliopoulos G.M., Wennersten C., Venkataraman L., Moellering R.C. Jr., Ferraro M.J. Lancet. 358:2001;207.
17. Jones R.N., Della-Latta P., Lee L.V., Biedenbach D.J. Diagn. Microbiol. Infect. Dis. 42:2002;137.
18. Auckland C., Teare L., Cooke F., Kaufmann M.E., Warner M., Jones G., Bamford K., Ayles H., Johnson A.P. J. Antimicrob. Chem. 50:2002;743.
19. Atarashi S., Yokohama S., Yamazaki K., Sakano K., Imamura M., Hayakawa I. Chem. Pharm. Bull. 35:1987;1896.
20. Hoogkamp-Korstanje J.A.A. J. Antimicrob. Chem. 40:1997;427.
21. MICs determined following NCCLS guidelines. (National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard, 5th ed; NCCLS document M7-A5; NCCLS: Wayne, PA, 2000). Bacterial strains listed in Table 1 were obtained from Pharmacia Kalamazoo, MI, USA) and include: SA1009: clinical isolate of S. aureus; SA1011: ATCC29213; SA1012: in vitro selected linezolid-resistant strain derived from SA1011; EF4010 and EF4016: clinical isolates of E. faecium; EF4008 and EF4011: isogenic linezolid-resistant strains isolated from same patient as EF4010 and EF4016, respectively. HI1008: clinical isolate of H. influenzae; MC1002: clinical isolate of M. catarrhalis; EC1008: clinical isolate of E. coli.
22. A standard supercoiling assay using reagents and protocols obtained from TopoGen Inc., Columbus, OH, USA, was used to evaluate inhibitory activity of this compound.